16:31 , May 4, 2018 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

CNP520: Phase II started

Novartis and Amgen began the double-blind, placebo-controlled, international Phase II Alzheimer’s Prevention Initiative (API) Generation Study to evaluate intramuscular CAD106 at weeks 1, 7 and 13 and quarterly thereafter or once-daily oral CNP520 for...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

CAD106: Phase II started

Novartis and Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) began the double-blind, placebo-controlled, international Phase II Alzheimer’s Prevention Initiative (API) Generation Study to evaluate intramuscular CAD106 at weeks 1, 7 and 13 and quarterly thereafter...
07:00 , Sep 14, 2015 |  BioCentury  |  Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Cytos, Novartis deal

Novartis will pay Cytos CHF4 million ($4.2 million) to eliminate payment obligations for CAD106, an Alzheimer’s disease (AD) vaccine the companies discovered under a 2001 deal. Novartis is developing the vaccine containing beta...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Company News

Novartis, Banner Alzheimer’s Institute (BAI) deal

Novartis partnered with not-for-profit BAI to evaluate two of the pharma’s compounds in cognitively healthy adults who have two genetic copies of the apolipoprotein E (APOE) epsilon 4 allele and are, according to the...
07:00 , Jul 28, 2014 |  BioCentury  |  Product Development

Still betting on Abeta?

This month's Phase II data neither proved nor disproved AC Immune S.A.'s hypothesis that it could dial out enough toxicity in crenezumab to enable a higher, more efficacious dose for AD than previous anti-beta amyloid...
00:46 , Jul 16, 2014 |  BC Extra  |  Company News

Novartis, Banner partner on Alzheimer's trial

Novartis AG (NYSE:NVS; SIX:NOVN) partnered with not-for-profit Banner Alzheimer's Institute (BAI) (Phoenix, Ariz.) to evaluate two of the pharma's compounds in cognitively healthy adults at risk of developing symptoms of Alzheimer's disease because they have...
07:00 , May 9, 2013 |  BC Innovations  |  Targets & Mechanisms

AD vaccine redux

Researchers at Harvard Medical School have teamed up with vaccine maker Mercia Pharma Inc. to design a next-generation Alzheimer's disease vaccine with an adjuvant that promotes a beneficial anti-inflammatory response that the team hopes...
07:00 , Oct 24, 2011 |  BioCentury  |  Product Development

AD pipeline: Immunotherapies

AD pipeline: Immunotherapies Company Product Description Status Baxter International Inc. (NYSE:BAX) Gammagard Liquid 10% Plasma-based therapy containing IgG antibodies Ph III Eli Lilly and Co. (NYSE:LLY)...